These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31128503)

  • 21. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
    Sindet-Pedersen C; Staerk L; Lamberts M; Gerds TA; Berger JS; Nissen Bonde A; Langtved Pallisgaard J; Hansen ML; Torp-Pedersen C; Gislason GH; Bjerring Olesen J
    Heart; 2018 Jun; 104(11):912-920. PubMed ID: 29092916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
    Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
    Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry.
    Jerjes-Sanchez C; Corbalan R; Barretto ACP; Luciardi HL; Allu J; Illingworth L; Pieper KS; Kayani G;
    Clin Cardiol; 2019 May; 42(5):553-560. PubMed ID: 30873623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin K antagonists but not non-vitamin K antagonists in addition on antiplatelet therapy should be associated with increase of hematoma volume and mortality in patients with intracerebral hemorrhage: A sub-analysis of PASTA registry study.
    Nomura K; Suda S; Abe A; Iguchi Y; Yagita Y; Kanzawa T; Okubo S; Fujimoto S; Kimura K;
    J Neurol Sci; 2023 May; 448():120643. PubMed ID: 37028263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
    Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
    Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
    Verheugt FWA; Ambrosio G; Atar D; Bassand JP; Camm AJ; Costabel JP; Fitzmaurice DA; Illingworth L; Goldhaber SZ; Goto S; Haas S; Jansky P; Kayani G; Stepinska J; Turpie AGG; van Eickels M; Kakkar AK;
    Am J Med; 2019 Dec; 132(12):1431-1440.e7. PubMed ID: 31306621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.
    Pottegård A; Poulsen BK; Larsen MD; Hallas J
    J Thromb Haemost; 2014 Sep; 12(9):1413-8. PubMed ID: 25039280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulant selection in relation to the SAMe-TT
    Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
    Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New advances in the treatment of atrial fibrillation: focus on stroke prevention.
    Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Oct; 15(15):2193-204. PubMed ID: 25112657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
    Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
    Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.
    Bassand JP; Virdone S; Badoz M; Verheugt FWA; Camm AJ; Cools F; Fox KAA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Misselwitz F; Pieper KS; Turpie AGG; van Eickels M; Kakkar AK
    Blood Adv; 2021 Feb; 5(4):1081-1091. PubMed ID: 33606006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.